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Patient to patient variability is one of the issues when administering medications to individuals 
with different health conditions, pharmacokinetic, age, fitness, gender, and race. This requires 
introducing smart and personalised drug delivery systems with controlled release profile 
manufactured using novel approaches. Additive manufacturing (AM) provides opportunities 
such as full customisation, design freedom, and on-site manufacturing, and materials recycling. 
As a result, the academic and industrial demand for additive manufacturing for drug delivery 
has been continuously increasing and showing impressive results for a wide range of products. 
This paper provides an extensive overview of AM technologies and their applications for drug 
delivery. The review discusses AM technologies including their working principles, processed 
materials, as well as current progress in drug delivery to produce personalized dosages for every 
patient with controlled release profile. AM potentials, industrial scale, and challenges are 
investigated with regards to practice and industrial applications. The paper covers novel 
possibilities of AM technologies and their pharmaceuticals applications, which indicate a 
promising healthcare future. 
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1. Introduction  
 
The rise of Industry 4.0, also known as digital technology, makes factories smarter, and helps 
manufacturers to enhance quality, productivity, and profitability. Additive manufacturing 
(AM), an important pillar of digital technology, is a manufacturing tool that has been 
progressing over the last three decades. The technology was first invented by Charles Hull in 
1986 using UV sensitive polymers and ultraviolet (UV) light to create 3D objects (Prasad and 
Smyth, 2016). The technology was later known as Stereolithography Apparatus (SLA). Since 
then, scientists and engineers have developed various novel AM techniques. Currently, there 
are many commercially available AM equipment and many more innovative concepts are still 
under investigation. The increasing demand for AM is set to continuously generate more 
investments and introduce many thousands of new jobs. A report by the World Economic 
Forum in Davos demonstrated that most of today’s children would have jobs related to industry 
4.0 (Schwab, 2017). The technology has shown a great promise as a tool in both industry and 
research to fit with various industrial demands. 
 
Benefits of AM can be summarized as follows: 
1- Shortened lead-time; 
2- Mass customization with no additional processing; 
3- Improved supply chain competence; 
4- Printing assemblies and systems; 
5- Manufacturing functional parts with complex geometries; 
6- Lightweight manufacturing of cellular structures; 
7- Materials recycling and sustainable manufacturing; 
8- Scalable workflow; 
9- On-demand manufacturing of parts; 
10- Quality improvement of services. 
 
In AM, different materials such as polymers (Klippstein et al., 2018b), metals (Qiu et al., 2015), 
and ceramics (Essa et al., 2017) can be built layer-by-layer to achieve the required geometry 
according to a digital design, which is different from conventional manufacturing or forming 
techniques where the required geometry is achieved by subtracting or forming. AM 
technologies have been used in many sectors, such as biomedical (Hassanin et al., 2018), energy 
(Sabouri et al., 2017), aerospace (Galatas et al., 2018; Klippstein et al., 2018a), and defence (Li 
et al., 2016). This can be attributed to capabilities of AM technologies to create complex designs 
rapidly with high degrees of precision and accuracy, in addition to their ability to recycle 
materials. These benefits and advantages have attracted the attention of many researchers and 
industrial organisations to enable AM for broader adoption and investigate their capabilities 
and limitations. This can be clearly seen in the increased number of published papers and 
patents on using AM/3D printing technology over the last ten years (Figure 1a). The number of 
published papers increased from below 500/year in 2008 to over 6000/year in 2018. In addition, 
the numbers of patents filed have raised from just above 2000/year in 2008 to over 7000/year 
in 2018.  
Drug delivery represents a group of technologies used to safely introduce a pharmaceutical 
material into the body for a specific therapeutic effect (Tiwari et al., 2012). Recently, the 
technology has significantly progressed in all of its aspects ranging from oral tablets to drug 
eluted implants. The concept of pharmaceutical delivery is based on the incorporation of a drug, 
the release of its active materials, and the subsequent passage of such materials to the site of 
action. Patient-to-patient variability is considered as a challenge when administer patients with 
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a drug delivery solution. Pharmaceutical manufacturing techniques such as capsule filling and 
tabletting have been advanced, particularly with respect to controlling drug-releasing profile 
using approaches such as nano-particles, functionalized liposomes, and biomimetic particles. 
However, the associated research and scaling-up costs are barriers to advance drug delivery 
systems using these approaches. In the past decade, advanced drug delivery have been 
introduced because of the advancement of several manufacturing technologies and hence many 
research activities have been carried out in this area. Figure 1b shows statistical data of 
published papers and patents on drug delivery using AM technologies from 2008-2018. As 
shown, initially, the papers number grows then picked up significantly after 2012. The 
published paper number has been increased from 120/year in 2008 to more than 3000/year. On 
the other hand, there was a prompt rise in 2018 reaching to approximately 1725 patents in that 
year. This paper reviews the use of AM technology and its capabilities for different drug 
delivery approaches including oral solid medications, transdermal patches, vaginal and rectal 
drug delivery, and drug-loaded implants and scaffolds. The general processing concept, 
potentials, and challenges of each AM tools are discussed in details. In addition, the research, 
industrial progress, and outlook are also summarised. 
 
 
Figure 1: (a) number of published papers and filed patents on 3D printing over the last 10 
































































2. Drug Delivery Technologies  
A medication can be introduced into a patient body using several techniques to achieve a 
systemic biological effect and treat certain diseases. These techniques are generally classified 
by the body location at which the pharmaceutical materials are targeted. The choice of a drug 
delivery method depends on factors including disease, the desired effect, the performance of 
the drug effective materials, and in some cases patients’ preferences. Additive manufacturing 
has revolutionised the drug delivery industry towards personalisation medication. Additively 
manufactured drug delivery workflow is shown in Figure 2. A typical AM drug delivery system 
starts with a laboratory examination, which may include computed tomography scanning (CT) 
or magnetic resonance imaging (MRI).This offers useful data regarding the patient condition 
and the design requirements aiming to achieve patient centred dosage form and a programed 
release profile. This is followed by preparation of treatment plan, which may include the desired 
administered drugs and their desired release profile. AM technology has the capability not only 
to provide personalised medication but also capable to deliver programmable drug release. 
Next, a digital model is created using computer aided design (CAD). Finally, drug loaded 
delivery system is produced using additive manufacturing to be administered into routes such 
as oral solid medications, intravenous devices, rectal and vaginal delivery, transdermal patches, 
intravenous devices, biomedical implants, and scaffolds drug delivery.  
 
 
Figure 2: Additively manufactured drug delivery systems workflow and their available body 
routes. 
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2.1. Oral Solid Medications 
Oral solid medication can be considered is the oldest and the most well-known drug 
administering technique. It is cheap, easy to use, non-invasive and has high absorption 
properties. Different forms of this technique are available such tablets, pills, capsules, troches, 
lozenges, films and pellets (Al-Hashimi et al., 2018; Hassanin et al., 2017; Prausnitz and 
Langer, 2008). However, there are limitations of oral solid medications such as the variability 
of release profile, medication concentration, and the decomposition of some drug formulation 
due to their sensitivity to low pH values existing in human digestive system before reaching the 
body part of interest. Typically, oral solid medications are manufactured using powder 
processing routes. This includes powder preparation, blending, milling, granulation, 
compression, and hot-melt extrusion. Despite these techniques have been around for more than 
50 years, powder processing is still the preferred manufacturing technology for innovations in 
oral drug delivery. This is because they are reliable processes, and are less prone to typical 
malfunctioning issues. However, the current conventional manufacturing technologies faces 
several challenges of issues such as patient variability and hence cannot fulfils the demand of 
personalised medication. In addition, a study found that was less than 50% of patients with 
chronic diseases achieve drugs goals and majority of the patients do not adhere to their 
medication. This is related to health complications, high morbidity and early mortality rates 
besides the high healthcare costs (2003). Polytherapy and dosing regimen are amongst the 
factors that worsen patients’ compliance.  Pill burden is associated with suboptimal clinical 
outcomes and pharmaceutical companies have tried to overcome this issue by introducing fixed-
dose combination therapy (FDCT) where two medications are combined in one tablet. 
Glucovance®, Avandamet®, and Metaglip™ are FDCTs that were approved between 2000-
2002. Some improvement of FDCT is well reported in the literature (Blonde et al., 2003). 
Nevertheless, FDCT does not offer dose flexibility, which could vary from patient to patient. 
Moreover, FDCT combines anti-diabetic drugs only. For example, diabetes mellitus which is 
one of the most widespread conditions is usually associated with cardiovascular and kidney 
diseases as they share a similar pathophysiological pattern. In a study by Alonso-Moran, around 
90% of diabetes patients were multi-morbid and had heart failure, hypertension, kidney 
problems, ischaemic heart disease, atrial fibrillation, mental problems, digestive, bone or joint 
diseases (Alonso-Morán et al., 2015). Multi-morbid Diabetes patients are usually on 
polytherapy that in turn worsens their adherence to medication and causes deterioration in their 
health condition. A single and personalised tablet that combines all medications for patients 
with chronic diseases will significantly improve their compliance and adherence to treatment. 
AM technology allows administered oral medication to be personalised in different structure, 
shapes, release profile, and included with multiple drugs that are challenging to achieve using 




Figure 3: Additive manufacturing of oral dosage medication (Goyanes et al., 2015b; Goyanes 
et al., 2015c; Khaled et al., 2014; Khaled et al., 2015b; Okwuosa et al., 2017; Rowe et al., 
2000; Sun and Soh, 2015; Yu et al., 2009a) 
 
2.2. Rectal and Vaginal Medications    
Rectal drug medication administer drugs to rectum. The medication is absorbed through the 
rectum's vessels that deliver it to the body's circulatory system. Rectal medications have been 
utilised for hundreds of years especially for elderly people and children (Hua, 2019). However, 
some cultures and countries neglect or avoid the use of this technique due to cultural barriers 
and privacy concerns. Despite the route restrictions, rectal administration is a recommended 
technique for unconscious, reluctant, vomiting and difficult to swallow patients. Several forms 
of rectal drug delivery are available such as rectal capsules, suppositories, ointments, creams, 
and gels. The technique has many benefits over oral drug delivery such as bypassing the 
enzymatic activities in the gastro intestinal tract; hence, a safer approach for sensitive drugs, 
partially bypassing the first pass metabolism, high performance for localized treatments for 
some conditions. Challenges that prevent the wide use of this mythology are the high inter-
individual variability and low/variable absorption efficiency of the rectum. Efforts must be 
carried out to tackle these difficulties by developing personalised dosage form with controlled 
drug release, and muco-adhesive dosage forms. Like rectum, women vagina has been also 
utilised as a location of drug delivery since ancient times. Many forms and shapes of vaginal 
medications are available such as pessaries, tablets, solutions, gels, suppositories, and vaginal 
rings which are in use to treat a number of conditions such as osteoporosis, contraception 
hormone replacement therapy, infertility, infections, and other related conditions (Jain, 2008; 








Jain, 2014). This is because of the several benefits such as low enzymatic activity, high 
vascularization, and avoidance of metabolism. Other benefits include easy access, the 
prolonged retention of medication, and the excessive permeation of the place (Hussain and 
Ahsan, 2005).  Several researches introduced vaginal and rectal devices with various shapes 
and eluting medications, see Figure 4. 
  
 
Figure 4: Additive manufacturing of oral dosage medication (Fu et al., 2018; Krezić et al., 
2020; Smith et al., 2013; Tagami et al., 2019) 
 
2.3. Intravenous Devices 
Intravenous devices are used in drug delivery by an intravenous injection or infusion into a 
body vein using a tube or a needle. They are typically used in situations at which there is an 
essential need to control medications into the body or when patient must have the medication 
quickly into the bloodstream such as in emergency or when oral medications would be break 
down during metabolism (Peterfreund and Philip, 2013). There are different types of 
intravenous devices and the most common one is the standard intravenous device, which is used 
in short-term situations such pain relief, antibiotic, and nausea medications. With standard 
intravenous, a needle is typically inserted into a vein in the wrist or the back of the hand. Next, 
a catheter is pushed over the needle then the needle is removed, while the catheter stays in the 
vein. Push intravenous devices are another type which employed by an intravenous infusion or 
injection directly into a body vein using a push of a syringe. On the other hand, catheter is a 
AM of rectal and vaginal 
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long tube that deliver medication from a vein near the elbow, chest or neck to a vein near the 
heart (Hallaj-Nezhadi et al., 2010). Additive manufactured intravenous devices was focused on 
the development of customised catheters to for local drug delivery, see Figure 5.  
 
 
Figure 5: Additive manufacturing of eluting catheters.  
2.4. Transdermal Medications 
Transdermal patches are a type of drug delivery systems that are used to introduce medications 
through the skin for curative purposes and to replace other drug delivery systems. For many 
centuries, people have used different materials to treat various skin diseases. Nowadays, a wide 
range of topical products has been introduced to achieve therapeutic effects. The first 
transdermal medication was approved by the FDA for more than 40 years. An example of 
commercially transdermal drug delivery is the nicotine patch which was made available in the 
late eighties (Jain, 2008; Jain, 2014). Typically, transdermal drug delivery consists of direct 
skin formulations such as gels and creams, drug carriers, penetration enhancers, and patches. 
Transdermal medications methods have demonstrated several advantages; they are easy to use, 
cheap, non-invasive, self-administered, and have prolonged release profiles. In addition, the use 
of such systems enables the drug to avoid liver metabolism associated with oral drug delivery. 
Compared to injections, transdermal medication is not painful and does not transmit diseases 
associated with needle re-use. However, the density and the impermeability of stratum corneum 
, the outer layer of the skin, makes it difficult for medications to penetrate across the skin at 
desired rates. As such, the development of advanced transdermal drug delivery with improved 
characteristics has become the subject of intensive research and the potential of advanced 
technologies is broadly considered (Prausnitz and Langer, 2008). Microneedles patches are the 
most common applications of transdermal medications. They have microscopic needles used to 
deliver medications through skin. The size of microneedles can in range of 150–1500 µm long, 
50–250 µm wide, and have 1–25 µm tip dimension. Therefore, micro fabrication techniques 
such as soft lithography have been used to fabricate microneedles with high reloustion (Iliescu 
et al., 2017), though it was typically used to replicate polymers and ceramics micro 
parts(Hassanin and Jiang, 2009b; Hassanin and Jiang, 2011; Hassanin and Jiang, 2013a; Zhu et 
al., 2010). However, soft lithography requires many fabrications steps and special equipment 
to fabricate fine micro parts (Hassanin and Jiang, 2009a, 2010a, b, 2013b). Drug coated and 
uncoated eluting microneedle patches were developed using AM, which provides many 










2.5. Implants, Scaffolds, and Surgical Meshes  
Biomedical implants are devices placed inside the body to achieve a variety of functions or to 
replace a missing body tissue. Recently, there has been a growing merging between biomedical 
implants and drug delivery. Novel implants have succeeded to improve patients’ quality of life, 
therapeutic effectiveness, and improved patient safety. Many researchers have developed novel 
implants with site-selective and controlled drug release profiles. High-performance implants 
with the controlled release of medications are of interest in different applications. Typically, 
implantable drug release methods can be classified into physical & chemical systems. The 
physical release system is based on the absorption of the medication through a specific 
polymeric matrix or coating. Stents, for example, are fitted with drug-loaded coatings that serve 
as a medication delivery system. The thickness of the coating material allow a varied control 
over the medication release profile. Furthermore, the drug in these devices can be included 
within or surrounded by the coating material, which allows further control over drug release.  
On the other hand, chemical-based delivery systems work by techniques such as degradation, 
swallowing the drug carrier or by splitting of chemically bound drugs. The swelling properties 
of chemically drug-loaded systems such as hydrogels are controlled with the change in 
surroundings temperature, pH, or the electrical field. Materials used in biomedical implants 
include biocompatible polymers, ceramics, and metals. Technologies used to manufacture these 
materials are well-established. However, novel implantable drug delivery systems is moving 
towards the personalisation and customisation, which are difficult to achieve using 
conventional manufacturing. Biomedical scaffolds are used as a template to guide cell 
attachment, differentiation, proliferation tissue growth, and to support new viable body tissues 
for a medical purpose. Scaffolds requirements include high biocompatibility, adequate porosity 
that mimics the natural body tissue and allows the transportation of body fluid, sufficient 










mechanical characteristics, and controlled biodegradability. Scaffolds are also used as a mean 
of drug delivery devices (Elsayed et al., 2019; Hassanin et al., 2017). During the last few years, 
scaffolds loaded with drugs were used to stimulate the recovery of bone conditions and prevent 
infections. Scaffolds with loaded drugs are capable of delivering high drug concentrations to 
the target location. Traditional techniques of the fabrication of scaffold implants include 
compression, solvent casting, hot melt extrusion, and injection moulding. In this context, 
several researchers have reported that the manufacturing technique of scaffold drug delivery 
would significantly affect the amount and the quality of the porous structure, degradation rate, 
and subsequently its drug release profile. 
On the other hand, surgical meshes have been used since 1891 to support body organs during 
surgeries. They are woven sheets made from biological or biocompatible inorganic materials. 
They are two types of meshes, temporary and permanent. Temporary meshes decompose over 
the time, whereas permanent ones remain in the body. Hernia and pelvic repair surgeries are 
the most common practices to use surgical meshes. Surgical meshes must allow the repair of 
fascial defect and tissue growth, have high strength, and maintain minimum adhesions to body 
tissues. Polypropylene (PP) is the most common polymer material used for the manufacturing 
of permanent surgical meshes. However, there are evidences of developing infection, chronic 
pain, and hernia recurrences. Therefore, efforts have been invested in developing novel meshes 
to improve these issues (Baylón et al., 2017). Drug coated and eluting implants, meshes, and 
scaffolds were introduced using AM to add functionality to the device such as healing, 
preventing an infection, or to reduce pain, see Figure 7. 
 
 
Figure 7: Additive manufacturing of implants, meshes and scaffolds drug delivery (Cox et al., 
2016; Hassanin et al., 2018; Mohanty et al., 2015) 
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3. AM Technologies for Drug Delivery 
There are wide ranges of AM techniques that are currently available in the market. A 
standardised classification of these technologies is introduced by the American society of 
testing and the international organization for standardization (ISO/ASTM). This standard is the 
AM ISO/ASTM 52900:2015, which categorises the well-established AM techniques into seven 
main groups; Material Extrusion, Powder bed fusion, Vat Photo Polymerisation, Direct Energy 
Deposition, Binder Jetting,  Material Jetting, and Sheet lamination (Table 1). The next section 
discusses the concept of each group and its application in drug delivery.  
 
 
Table 1: The standardised AM technologies 
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3.1. Material Extrusion (ME)  
Material extrusion is characterised by fairly low cost and high speed (Ngo et al., 2018). In ME, 
the material is heated until softened and extruded under pressure through a narrow nozzle 
following the path of the part digital model. The extruded thermoplastic or paste material is 
then dropped on top of the building platform and solidify upon cooling. Fused deposition 
modelling (FDM) is a popular technique of ME where the printed materials must be 
thermoplastic to allow the extrusion and the adhesion with previous layers. The technique is 
shown schematically in Figure 8a. Examples of thermoplastic used in FDM include 
thermoplastic polyurethane (TPU), polylactic acid (PLA), and acrylonitrile butadiene styrene 
(ABS). Metal/thermoplastic and ceramic/thermoplastic composites materials were also utilised 
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by FDM to print out composite parts with added functionality. Gels and pasts can be also 
extruded with the aid of pressure as in pneumatic or syringe extrusion (PE/SE) techniques. The 
PE/SE process starts with filling the syringe with a printing material; then the material is 
extruded through the nozzle , see Figure 8b. The advantages of using pneumatic or syringe 
extrusion (PE/SE) over FDM is that they can be utilised to print several materials at low 
temperatures without the need to melt them (Lim et al., 2018). Bioprinters based on PE/SE 
systems are capable of printing biomedical objects with high precision using small nozzles 




Figure 8: Schematic diagrams of (a) fused deposition modelling; (b) pneumatic or syringe 
extrusion (PE/SE). 
 
Material extrusion is the most AM technology adopted for many drug delivery routes (oral, 
rectal, vagina, transdermal, scaffolds, and implants). Both FDM and PE have been implemented 
to manufacture oral solid tablets because of their ability to deal with a wide range of 
biocompatible materials. Many researchers have extensively investigated the use FDM’s ability 
to produce several forms of oral drug products, including tablets, capsules, and beads. A 
summary of the literature use of FDM in oral drug delivery is summarised in Table 2. As can 
be seen from this table, the vast majority of the literature has been focused on development of 
FDM printed tablets with controlled drug profile. Releasing medication in a timely manner is 
essential for optimal drug effect in the human body. Different types of controlled drug release 
are necessary to be implemented according to patient condition. For example, constant drug 
release is an important type as it has a narrow concentration range in which the medicine can 
work efficiently in the body. Below the required concentration, the drug will not be effective 
while above it unfavourable side effects may occur. 3D printed tablets and caplets have been 
fabricated with different infill density, drug-loading contents, and complex structure aiming to 
achieve immediate or extended release profile. Materials used as the matrix include PVA, 
Irgacure, PLA, HPC, and HPMC. On the other hand, a wide range of drugs has been 
experimented such as Curcumin, Paracetamol, Caffeine, Orange G, Fluorescein, 
Acetaminophen, and Prednisolone. Figure 9 shows porous paracetamol and caffeine printed 
tablets and their drug release profile (Goyanes et al., 2014). The results show that all printed 
samples released the entire loaded drug in less than 480 minutes. It was also found that the drug 






Figure 9: FDM printing of porous paracetamol- and caffeine-based tablets and their and drug 
release profiles (Goyanes et al., 2014). 
 
Aiming to reduce the administered medication to patients, FDM was implemented to develop 
sustained release intragastric floating and poly pills drugs. (Chai et al., 2017) used FDM to 
prepare Domperidone based tablets to be used as a floating intragastric system for a sustained 
release aiming to enhance its oral bioavailability and simplifying the schedule of the given 
prescription. Hot-melt extrusion technique was used to load Domperidone into hydroxypropyl 
cellulose (HPC) filaments. Results showed that the tablets exhibited a sustained, controlled 
release and were able to stay floating for more than 10 hours in vitro. It also retained inside 
rabbits stomach for more than 8 hrs, see Figure 10. On the other hand, (Okwuosa et al., 2017) 
developed poly pill medication with shell-core structure using dual FDM 3D printer. The results 
showed the potential of using FDM to introduce multiple drugs in the same tablets with different 
release profile. Poly-pills or poly-therapy have been widely explored with pneumatic extrusion 
technique (PE) (Khaled et al., 2014; Khaled et al., 2015a, b). One of the studies introduced by 
Khalid et al. explored the use of PE to develop a polypill five different drugs and with two 
independently release rate and concentration. The developed tablet showed that complex drugs 








Figure 10: (a) Images of 3D printed tablets (b) X-rays showing the positions of the 3D printed 
medication in the gastrointestinal tract of rabbits at several time intervals, (Chai et al., 2017). 
 
 
Table 2: Material extrusion technology for oral drug delivery applications. 
AM 
Tech 
















• PLA  
• IRGACURE 184 
• HPC 




• Eudragit EPO 
• MMC 
• TCP 
• Methacrylic acid 
• PCL 













• 5-ASA captopril 
• Theophylline 
•  Prednisolone 
Soaking, 
mixing/milling 
(Beck et al., 2017; 
Genina et al., 2016; 
Goyanes et al., 2014; 
Goyanes et al., 2015a; 
Goyanes et al., 2015b; 
Goyanes et al., 2017; 
Goyanes et al., 2016b; 
Goyanes et al., 2015d; 
Jamróz et al., 2017; 
Okwuosa et al., 2017; 
Okwuosa et al., 2016; 
Pietrzak et al., 2015; 
Sadia et al., 2016; 
Skowyra et al., 2015; Sun 
and Soh, 2015; Tagami et 
al., 2017; Zhang et al., 
2017a) 
Intragastric floating 
tablet with extended & 
sustained release 
• HPC 
• Eudragit L100 
• HPMC 
• DOM Mixing (Chai et al., 2017) 
Multiple-drug based 
tablets with controlled 
release 
 

















tablets with controlled 
release 
• PEG 6000 
• D-mannitol 
• Cellulose acetate 
• PVP K30 
• Sodium starch 
glycolate 
• HPMC 2208 
• MCC  
• HPMC 2910 
• PAA 
• Captopril 
•  Nifedipine 
•  Glipizide 
• Captopril 
•  Nifedipine 
•  Glipizide 










(Khaled et al., 2014; 





2hr 4hr 6hr 
8hr 10hr 12hr 
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Conventional rectal, vaginal drug delivery, transdermal patches and dressing do not consider 
specific patients’ needs, health conditions, and anatomy, which restrict patient adherence to 
medication as well as the medication effectiveness due to the biological and physical 
differences between patients. Recent progress in AM helped to introduce solutions to the 
inherited issues of rectal and vaginal drug administration. Proof of concept studies of using ME 
technologies were carried for rectal and vaginal medications. Examples of vaginal and rectal 
drug delivery systems include rectal and vaginal suppositories, uterine systems, vaginal rings, 
and vaginal applicators, see Table 3.  (Krezić et al., 2020) developed personalised rectal and 
vaginal suppositories using FDM technology to prepare PLA moulds and Witepsol H 15 as 
suppositories formulation. Several studies have shown that the suppositories shape significantly 
affects the preferences and adherence to medicine for patients. Rocket-shaped, torpedo-shaped, 
and bullet-shaped suppositories were developed using FDM (Krezić et al., 2020).   
On the other hand, personalised and fixable shaped wound dressing and topical patches drug-
loaded systems were demonstrated by FDM, altered in size and geometry to patients (Goyanes 
et al., 2016a; Muwaffak et al., 2017). (Luzuriaga et al., 2018) used the FDM to fabricate high 
resolution microneedles, though the resolution of the printed parts were far from the 
microneedle geometrical requirements. The authors used an etching post processing to etch the 
printed parts down to the required shape.  
A Furthermore, (Welsh et al., 2019) investigated the use of PE to manufacture dapivirine loaded 
vaginal rings. The developed rings were compared to those produced using injection moulding. 
Different infill density of the rings were achieved using PE. The results showed that the 
developed rings outperformed the IM rings and it showed a great potential to control release 





Figure 11: (a) Manufacturing process of PE vaginal ring; (b) drug release profile when 
compared to IM rings (Welsh et al., 2019).  
  
Table 3: ME technology for Rectal, vaginal and transdermal patches drug delivery systems. 
AM 
Tech 













Rectal and vaginal 
suppositories 
• PLA for the mould 
• Witepsol H 15 
• None None (Krezić et al., 2020) 
Suppository shell • Polyvinylalcohol • Progesterone None (Tagami et al., 2019) 
Vaginal 
applicators 
• ULTEM 908 • Soft tissue-
PMMA 







• Indomethacin Mixing 
 
(Genina et al., 2016; Holländer et 
al., 2016) 
Personalised nose 
acne patch  
• PCL 
• FPLA 




(Goyanes et al., 2016a) 
Drug loaded 
wound dressing  




(Holländer et al., 2016) 
Microneedle 
patches 
• PLA • N/A N/A (Luzuriaga et al., 2018) 
 
PE 




Hot mixing (Fu et al., 2018; Welsh et al., 
2019) 
 
Bone is a complex connective tissue made up of cells, fibres and minerals. It is different from 
other connective tissues with unique features at which the extracellular components are 
mineralized, giving it significant strength and rigidity, which allows it to play a major role 
within the body such as supporting the structure of the body and allowing the skeletal 





technologies such as FDM and PE have facilitated the manufacturing of implants and scaffolds 
with loaded drugs, see Table 4. On-demand, intraoperative FDM of surgical meshes have to 
enable patient-specific medicine for localized drug delivery aiming to avoid systemic toxicity 
and achieve required therapeutic levels (Ballard et al., 2017). PLA filament loaded with 
gentamicin was used to print the bioactive meshes, see Figure 12.  A printed mesh to chemically 
treat pancreatic cancer were fabricated using PE. PCL (PLGA/PCL) and PLGA were loaded 
with 5-FU and printed as a patch. The results showed a successful delivery of a high 
concentration of chemotherapy drug at the site of a tumour. It also showed that the developed 
5-FU-PLGA/PCL patches revealed a minimum side effect, prolonged-release period, the 
attachable flexibility, and a substantial suppressive on the growth of cancer (Yi et al., 2016). In 
another study, (Long et al., 2019) developed chitosan-pectin wound dressing contains lidocaine 
loaded hydrogel. Figure 13 shows the PE printed hydrogels with high quality, self-adhesion and 
dimensional integrity to skin. The 3D printed samples showed high swelling amount and good 
absorption of water, which revealed a suitable moist wound healing environment. Additionally, 
polyurethane loaded with levofloxacin for soft tissue reinforcement in vaginal surgery 
(Domínguez-Robles et al., 2020), polycaprolactone loaded with stem cells for pelvic floor 
application (Paul et al., 2019), and polypropylene loaded with ciprofloxacin antibiotic were all 
developed using FDM technology (Qamar et al., 2019).  
 
,  
Figure 12: (A) Mesh CAD model. (B) FDM printed mesh. (C) SEM image at 25× presenting 
developed mesh fibres. (D) SEM image at 1,000× magnification presenting loaded gentamicin 





Figure 13: (a) Chitosan-pectin (CS-PEC) hydrogel printing using PE (Long et al., 2019). 
 




















implants and surgical 
meshes  
• PLA 











Mixing (Ballard et al., 2017; Boetker et al., 
2016; Chou et al., 2017; Misra et al., 
2017; Sandler et al., 2014; Water et al., 


































Mixing (Ahlfeld et al., 2017; Li et al., 2015; 
Min et al., 2015; Shim et al., 2015; 























Mixing (Ahlfeld et al., 2017; Li et al., 2015; 
Min et al., 2015; Shim et al., 2015; 
Zhang et al., 2014; Zhang et al., 2017b) 
 
(Weisman et al., 2019) developed a personalized drug delivery in interventional radiology by 
enabling FDM to produce drug-loaded catheters. Bioactive-laden bioabsorbable catheters were 
loaded with chemotherapeutics and antibiotics by mixing and extruding PLA coated pellets. 
The chemotherapeutics and antibiotics were found dispersed into the PLA matrix. The results 
showed that the developed catheter had sustained drug release profile up to the 5 days and the 
antibiotics loaded catheters inhibited the bacterial infection as required, see Figure 14. Similar 
study was conducted by (Mathew et al., 2019) to use FDM technology to produce thermoplastic 
polyurethane loaded with tetracycline hydrochloride catheter with various drug contents. The 
results showed that tetracycline hydrochloride was dispersed within the polyurethane. In 
addition, the developed catheters showed a strong inhibitory influence on the bacterial growth 






Figure 14: (A) Antimicrobial effect of catheters (a) PLA, (b) PLA+ 1 wt% gentamicin, (c) 3D 
printed drug loaded catheters (Weisman et al., 2019). 
 
Table 5: ME technologies for intravenous devices. 
AM 
Tech 
















• Tetracycline hydrochloride  
Mixing (Mathew et al., 2019; Weisman et 
al., 2019) 
 
3.2. Vat polymerisation (VP) 
 
Vat polymerisation (VP) is one of the oldest AM approaches.  This technique uses UV light to 
chemically initiate the crosslinking of a selective layer of photosensitive resin and cure it into 
a solid polymer. Next, another layer of the photosensitive polymer is cured onto the previous 
layer. Spreading the resin material and curing it using UV layer is repeated until the part is 
completed, see Figure 15. Afterwards, the cured part inside the resin tank is removed. Post-
processing such as cleaning and heating can be applied to some materials to achieve better 
structural integrity and desirable mechanical properties. Metal and ceramic particles can be 
dispersed with the resin to achieve specific properties. The approach is one of the best AM to 
achieve high resolution, which can go as low as few microns. However, VP is relatively slow, 
expensive, and limited to photosensitive materials, which restrict its applications. VP 
techniques include Continuous Liquid Interface Production (CLIP), stereolithography (SLA), 








Figure 15: A schematic illustration of (a) stereo-lithography (SLA), and (b) digital light 
processing (DLP) 
 
VP technology has the ability to produce components with relatively high resolution and better 
precision than any other AM techniques. This is beneficial not only for fabricating highly 
complicated geometries necessary for personalised implants and transdermal delivery systems, 
but also for controlling drug release kinetics for oral tablets. Compared to FDM technology, 
SLA is a non-thermal process, which allows the printing of tablets incorporating thermo-
sensitive drugs and hence decreases medication degradation. Tablets containing paracetamol 
and 4-ASA were developed using SLA technique (Wang et al., 2016). In addition, SLA was 
used to produce suppository moulds to meet the needs of patients’ personalized medications 
(Sun et al., 2016). Transdermal microneedles were fabricated using SLA, CLIP and DLP 
technologies (Johnson et al., 2016; Kavaldzhiev et al., 2017; Lim et al., 2017; Yeung et al., 
2019). In one of the studies, polymeric resin was used to fabricate microneedle arrays for 
improved transdermal patch containing cisplatin for epidermoid skin cancer treatment. The 
developed microneedles were built by using SLA followed by a coating process at which 
cisplatin was deposited on top of the developed microneedles using inkjet printing. Figure 16 
shows SEM images of the printed samples with and without coating. The results revealed that 
the prepared microneedles had excellent piercing capacity with 80% penetration depth (Uddin 
et al., 2020). Several studies were carried out and showed that high performance microneedles 
can be fabricated by using SLA for insulin delivery (Economidou et al., 2019) and 
microencapsulated cell extrusion (Farias et al., 2018). In addition, SLA technique was used to 
print hydroxyapatite-coated scaffolds using SLA. The coated samples exhibited osteopromotive 
properties, see Figure 17. The results showed that bone regeneration was considerably enhanced 
using the HA-coated scaffolds. Further examinations showed that the scaffold had a rich 
microscale layer of HA that mimics bone materials and hence helps to improve the healing 
process (Guillaume et al., 2017). Other drug delivery devices such as rapid reconstitution 
packages and coated vascular stents were fabricated using SLA and CLIP, respectively (D’hers 






Figure 16: SEM images of the developed microneedles (a) uncoated (b) magnified uncoated 
(c) coated (Uddin et al., 2020).  
 
 
Figure 17: SLA of HA-coated scaffolds (Guillaume et al., 2017).  
Table 6: VP for drug delivery systems 
AM 
Tech 
Purpose of Use Materials Drug  Drug Loading References 







• 4-ASA  
• Paracetamol 
Mixing (Martinez et al., 2018; Robles-
Martinez et al., 2019; Wang et 
al., 2016) 






• Silastic Q7-4720 
• MED-4901  
• 3DM-Castable  
resin 
• Lidocaine  
• Ibuprofen sodium 
• Diclofenac sodium 
• Ketoprofen 





• PEG-PVA • Cisplatin N/A (Uddin et al., 2020) 
DLP • 3DM • N/A N/A (Lim et al., 2017) 
CLIP 
• PCL-tMa • Rhodamine 
• Fluorescein  
N/A (Johnson et al., 2016) 








• PTMC • Hydroxyapatite  
•  








• mPDC  
• Irgacure 819 
• Intrinsic 
• Antioxidant  




3.3. Binder Jetting (BJ) 
 
Binder jetting is one approach in which material powder are glued together according to a CAD 
design by using a jet of binder droplets deposited from a head on top of a layer of powder. The 
powder platform is then lowered to apply another powder layer onto the first one. The same 
procedure repeated until the part is fully completed. After the build is completed, a curing 
process takes place to strengthen the printed parts and help in separating them from the unbound 
powder. The benefits of this approach are that the parts can be created without the need for 
support structures. This is because of the lightweight materials used in this technique (powder, 
binder), which can be self-supported. A schematic diagram of the process is illustrated in Figure 
18. In addition, the available BJ systems are characterised with their low cost, relatively large 
build volume, and high print speed (Ferrari et al., 2018). A variety of materials (polymers, 
ceramics, metals) has been used in BJ systems. This includes stainless steel, Inconel, tungsten, 
glass, alumina, zirconia, nylon, and many others. The resolution range of this technique is 
around 200µm (Ferrari et al., 2018). The drawback of this technique includes the poor 
resolution, poor layer adhesion, and poor surface finish.  
  
 
Figure 18: Schematic diagram of Binder Jetting (BJ) 
 
Binder jetting process has been successfully implemented in the manufacturing of both oral 
solid tablets and drug-loaded biomedical implants, see Table 7. (Li et al., 2015) designed and 
printed complex and shaped geometries with controlled drug loading and releasing. They used 
solvent-free inkjet 3D printing to manufacture fenofibrate loaded tablets using beeswax, an 
FDA approved material, as a carrier of the medication. Figure 18 shows the manufacturing 
process to produce tablets with honeycomb structure. The process includes CAD design, 
printing, and drug releasing characterisation of the printed samples. Tablets with honeycomb 
geometries were designed with different cell size allowing the control over the surface area and 
hence the drug release profile. Similarly, other researchers studied the development of novel 
tablets with controlled pH formulation, gradient drug material, and complex geometries aiming 
to achieve fast disintegration and more control of drug release (Vorndran et al., 2010; Wu et 





Figure 19: Inkjet 3D printing of oral solid tablets. 
Drug loaded biomedical implants were also developed using inkjet printing. Most of the 
reported studies investigated the printing of PLA based implants. Huang et al. studied the 
utilisation of inkjet printing to develop levofloxacin, antibiotic, implants with complex drug 
release profiles. The antibiotic was loaded using powder mixing and milling of Polylactic acid 
(PLA) and the antibiotic. The authors found that PLA implants fabricated by inkjet printing 
exhibited a complex drug release profile when compared to implants fabricated using 
conventional techniques (Huang et al., 2007). Similar research works were also reported to 
develop PLA-based implants loaded with different drugs such as Isoniazid and Tobramycin 



























Table 7: Binder Jet technology applications for drug delivery 
AM 
Tech 
Purpose of Use Materials Drug  Drug Loading References 










Mixed  with powder 
polymer 
(Kyobula et al., 2017; Li et al., 2015) 
Tablets with multi 
and different pH 
based release 
profiles  
• Avicel PH301 
• Eudragit RLPO 
• Avicel PH301 





maleate    
• Diclofenac 
Mixed with powder 
polymer 
(Rowe et al., 2000) 
Tablet with 
material gradient 





• Stearic acid 
• APAP Mixed with powder 
polymer 
(Yu et al., 2007) 
Fast disintegrating 
tablets 






• Paracetamol Mixed with powder 
polymer 
(Yu et al., 2009b) 




implant with a 
slow-release 
profile  
• PLA • INH 
 
Mixed with a binding 
solution 
(Wu et al., 2014) 
Drug mixed 
implant (Tablet 





• PLA • LVFX Mixed with a binding 
solution 






release profile  
• PDLLA • LVFX 
• TOB 
Mixed with a binding 
solution 







• PDLLA • INH 
• RFP 
Mixed with binding 
solution 
 






• PLA • LVFX 
• RFP 
Mixed with binding 
solution 
(Wu et al., 2009a) 
 
3.4. Powder Bed Fusion (PBF) 
 
Powder bed fusion uses a heat energy source such as a laser or an electron beam to selectively 
melt or fuse materials particles according to digital design and create 3D objects layer by layer. 
The heat energy source is applied to a layer of powder, which incrementally drops down upon 
the completion of each layer. Next, another layer is spread onto the build platform. The group 
of techniques is widely used for advanced applications such as aerospace, automotive 
healthcare and defence. Laser or beam energy can be utilised for metal powders with relatively 
low melting points. Selective laser sintering (SLS), Selective Heat Sintering (SHS), electron 
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beam melting (EBM), Selective laser melting (SLM). SLM can be used to fully melt metal and 
alloy powders which results in nearly full dense parts with high mechanical strength while SLS 
and SHS can only elevate metal, polymer or ceramic powders surface temperature to be 
sufficiently fused without being melted, see Figure 20a (Ngo et al., 2018). On the other hand, 
EBM uses an electron beam gun to melt metal or alloy powders into the desired shape 
incrementally, see Figure 20b. 
 
 




Generally, powder bed fusion techniques are the least suitable methods for oral drug delivery. 
This is because the techniques are based on the use of a heat source to consolidate material 
powder, which may decompose the Active Pharmaceutical Ingredient (API). However, few 
studies were reported to use powder bed fusion (Table 8). Selective laser sintering was utilised 
to consolidate a mixture of drug and biopolymeric powder into personalised tablets. The tablets 
are typically with a porous structure to enable fast disintegration of the tablets. (Fina et al., 
2017) used SLS to consolidate thermoplastic biopolymers, namely, polyvinyl alcohol (PVA), 
polyethylene glycol copolymer (PGC), methacrylic acid (MA), and ethyl acrylate copolymer 
(EAC).  The polymeric matrix was mixed with different drug loading of paracetamol. The 
results revealed that it is viable to produce oral dosage with both immediate and controlled 
release profiles as shown in Figure 21 (a,b). In another study by the authors, SLS 3D printed 
medication-loaded tablets were produced with cylindrical bi-layer and gyroid lattice structures 
having customisable drug release characteristics, see Figure 21 (c,d). The figure shows a 
reduction in the time of the dissolution for the developed gyroid lattice structures which was 
attributed to the higher porosity and the increased surface area. As a result, additional water 
was able to penetrate through the formulation, resulting in a rapid drug release (Fina et al., 
2018a). Tailoring the internal structures according to the required drug release profile is another 
advantage of using AM in preparation of oral dosage. On the other hand, EBM and SLM have 
been used to develop drug-loaded implants and devices made from biocompatible metals and 
alloys. The capability of the two techniques to manufacture complex shaped objects enabled 
the development of personalised implants, scaffolds and devices with interact details. Ti6Al7Nb 
Implants was fabricated using SLM and surface coated with antibiotic. The surface coated 
biomedical implants exhibited a considerably lower cytotoxicity to osteoblast and fibroblast 
cells when compared to uncoated samples. Gentamicin, the antibiotic used, discharged from the 




saturated SLM orthopaedic implants have the ability to accelerate the recovery process and to 
decrease the infections risk significantly (Dydak et al., 2018). (Cox et al., 2016) investigated 
the development of Ti64 implants incorporating a reservoir filled with gentamicin loaded 
brushite cement using SLM process. They explored the influence of the reservoir microchannels 
orientation on the drug discharge. Figure 22 shows CT scan of the SLM implants loaded with 
antibiotic and different releasing channels. The results showed that the technique has the 
potential to manage release profile by changing the orientation of the implant releasing 
channels. Furthermore, electron beam melting was implemented to develop biomedical 
scaffolds loaded with drugs. Figure 23 shows the EBM scaffold before and after adding 
chitosan. The results showed that the biological growth of osteoblasts on developed scaffolds 
was greater than those without chitosan. This suggests that the Ti64/chitosan composite scaffold 







Figure 21: (a) SLS solid tablets with different drug loadings and polymer matrix, (b) drug 
release profiles for the printed samples, (c) CT images of drug-loaded tablets (d) drug release 







Figure 22: (a) CT scans of the drug-loaded reservoirs with different releasing channels 
orientation, (b) drug release profile with the corresponding channels (Cox et al., 2016).   
 
 


















Table 8: Powder bed fusion for drug delivery systems 
AM 
Tech 
Purpose of Use Materials Drug  Drug Loading References 












• Ibuprofen  
•  
Mixing (Fina et al., 2017; Fina et al., 2018a; 




• Ethyl cellulose • Paracetamol 
• Ibuprofen  
 
Mixing (Awad et al., 2019) 









• Silver  





Coating (Dydak et al., 2018; Vaithilingam et 
al., 2015; van Hengel et al., 2017) 
Drug eluting 
implants  
• Ti64 • Gentamicin 
• Vancomycin 
Reservoir  (Bezuidenhout et al., 2018; Cox et al., 











Coating (Ilea et al., 2019; Lin et al., 2019) 
Drug flow 
distributer  
• Ti64 • None None (Mazur et al., 2019) 











Impregnation  (Guo and Li, 2016; Liu et al., 2016; Lv 
et al., 2015) 
 
3.5. Material Jetting (MJ) 
In material Jetting (MJ), material droplets are being deposited through a print head building and 
dried by solvent evaporation or by solidification under ultraviolet (UV) light and the object is 
built layer by layer, see Figure 24. The technique was patented by Objet Ltd. in 1999 and 
merged with Stratasys in 2012 combining both photopolymers and Inkjet technology. The 
technology offers multiple colours, high-resolution builds, and high-quality surface finish 
objects. Materials used in this technique are limited to polymers and waxes because of their 
ability to form droplets and deposited through nozzles. Using wax as support material is 
beneficial as it can be melted and reused. Examples of polymer materials used in MJ include 
Polypropylene (PP), Polymethyl methacrylate (PMMA), polycarbonate (PC), Acrylonitrile 
Butadiene Styrene (ABS), high-density polyethene (HDPE), Polystyrene (PS), and High Impact 
Polystyrene (HIPS). The technology was evolved to include the deposition of droplets loaded 
with metal or ceramic particles. MJ has two commonly known processes; continuous inkjet 
(CIJ) printer and a drop on demand (DOD). They are different in the way the droplets are 
deposited and controlled (Shama, 2017). On continuous inkjet the material is deposited through 
the nozzles with the aid of continues pressure. The material drops are then positioned and cured 
using UV light (Derby, 2015; Goole and Amighi, 2016). Drop on demand (DOD) on the other 
hand deposits material only when required through a discrete pressure. Poly-Jet printing (PJP) 






Figure 24: (a) A diagram of Material Jetting, (b) continuous inkjet, (c) drop on demand.   
 
Several studies were found to investigate the use of material jetting to manufacture oral solid 
tablets, see Table 9. (Clark et al., 2017) developed a solvent-based ink formulation for the 
fabrication of oral medications that satisfy the standards needed for oral tablets, whereas 
allowing a flexible and personalized fabrication platform. The inkjet 3D printed tablets consist 
of both ropinirole and PEGDA. The drug release kinetics was shown to follow law type release 
profile with. Images of the additively manufactured tablets can be found in Figure 25. The 
tablets were translucent light yellow when compared to the clear ink solution (drug-free). The 
figure also shows small “banding” defects along the printing direction and small patches on the 
print surface. These defects can be minimised by optimisation of material and printing 
parameters. Although polyjet and multijet printing have been widely used to manufacture 
biomedical devices and prototypes, the two techniques have not well explored for drug delivery 
applications. (Xi et al., 2016) developed nasal spray pumps and nebulizers using PJP and tested 




Figure 25: (a) Images of ropinirole 3D printed tablets, (a) 5X magnification of the top 




















Materials Drug  Drug Loading References 










• Ibuprofen  
• Paracetamol  
• Indomethacin  
Mixing (Acosta-Vélez et al., 2018b; Clark et al., 2017; 










Mixing (Acosta-Vélez et al., 2018a) 





• Alginate None 
 












None (Xi et al., 2016) 
 
3.6. Direct Energy Deposition and Sheet Lamination 
In direct energy deposition (DED), energy is directed in a form of laser or electron beam into a 
focal region to melt material and deposit it through a nozzle on a heated substrate. A laser beam 
is used to meet with the feedstock in a powder or wire form at a focal point creating droplets of 
molten materials on a substrate layer by layer according to a predefined path, see Figure 26. 
The molten material is then fused and solidified on top of the substrate. Laser Deposition 
Welding (LDW), Laser Energy Net Shaping (LENS), and wire and Arc AM (WAAM) are 
different techniques of DED approach. Metals, alloys and their composites are mainly used in 
this approach such as stainless steel, titanium, aluminium, and nickel alloys. The approach is 
characterised by its high volumetric deposition rate, which can go ups to 10 Kg/h for WAAM 
technique. It is also characterised by its large build volume, which can go up to 6  m in length. 
However, the main drawbacks of this approach are its poor surface finish, poor accuracy, and 
the need for support structures for overhanging parts. As a result, the technique has been 
implemented in aerospace applications and has been used for cladding gas turbine engines, yet 
has not explored for drug delivery systems. Nevertheless, the technique was implemented to 
develop biomedical implants with improved surface modification (Balla et al., 2013; Bose et 
al., 2018; Shivaram et al., 2017). Sheet lamination (SL) on the other hand glue materials layers 
together and cut using either a laser beam or a knife. Localised ultrasonic energy can be also 
used to bond a stacked metal of accurately cut. Further machining and finishing can also be 
used after printing.  The bonded sheets are stacked layer-by-layer to build a 3D object without 
using any heat source according to digital design, see Figure 27. Materials used in this 
technique include paper, plastic, or metal laminates are used in manufacturing. SL can be 
considered also as a partly subtracted method because it follows the contours of the part and 
removes the rest of the sheet laminate. On the other hand, it is one of the fastest AM 
techniques for building complex parts. However, it is hard to avoid creation of defects in the 
interfaces of bonded layers. This tool is very beneficial when producing functionally graded 
materials multi-layers as different materials sheets can be included in the supplied rolls. 
Similar to DED, SL technique has not yet investigated for drug delivery applications. The 
process complexity, material limitation and the poorness of this technique could be the main 









Figure 27: Schematic diagram of Sheet Lamination 
 
 
4. Industrial Scale, Current Progress, and Challenges 
The growing demand of AM technologies and the significant cost decrease of commercial 3D 
printers, their accessories and materials, particularly within the healthcare sector, have 
resulted in the expansion of these technologies in many applications. AM global market size 
was $1.4 billion in 2010, compared to about $0.4 billion in 1996. The market value jumped to 
$9 billion in 2019 and is expected to surge to about $35 billion in 2024 as shown in Figure 28. 
The growth in the AM sales has also a similar trend, rising from only $71 million in 2001 to 
about $266 million in 2010 and are predicted to increase to $8 billion by 2025 (Caffrey, 2015; 











advantages of AM over other conventional manufacturing, there are also other interrelated 
factors, which can be identified to explain the rapid increase in the development of AM since 
2010. The first is the introduction of relatively affordable and accessible AM, which has 
facilitated the widespread applications of AM technologies across considerably wider 
communities of learners, researchers, and practitioners. Another factor was the introduction of 
efficient and user-friendly software and mobile applications for the modelling and 
implementation of complex designs which has allowed the public to create virtual 3D parts and 
accordingly build the aspiration to manufacture physical objects (Bourell, 2016). Many 
countries have introduced additive manufacturing as parts of educational programs in schools 
and universities (Wohlers et al., 2018).  
 
 
Figure 28: Revenue growth of AM worldwide (in billions of US dollars) from 2010 to 2024 
(predicted values for 2020-2024). 
 
The pharmaceutical industry undergoes a substantial shift from mass manufacture towards 
personalised medication and additive manufacturing has shown a great potential within drug 
delivery systems. In recent studies, GSK (GlaxoSmithKline) has successfully investigated the 
manufacturing of paracetamol tablets with rapid release profile. Typically, tablets comprises an 
active pharmaceutical ingredient (API) and a biocompatible binder substance. The tablets were 
loaded with paracetamol of up to (81%w/w), using PE 3D printer (Khaled et al., 2018b). The 
fabricated tablets released over 90% of the active phase just within 10 min. The developed 
paracetamol tablets did not show any degradation during printing and no interaction with the 
binding material (PVP K25 and NaCCS). The tablets was assessed and showed a controlled 
release and dosage by controlling the microstructure, composition and geometry of the printed 
tablets (Khaled et al., 2018a). Aprecia Pharmaceuticals was the first company that developed 
3D printed oral tablets (Spritam) in the market. The tablets is for treating epileptic seizures, and 
it is designed to disintegrate in the mouth in few seconds, which makes it suitable for patients 
who struggle to swallow solid tablets, pills, or capsules (spritam, 2019). The printed tablets 
were made with a design that allows them to be easily swallowed and disintegrates very quickly 
once the pill is taken. The tablet was approved by the U.S. Food and Drug Administration 
(FDA) in the year 2015 (Pharmaceuticals, 2019). Johnson & Johnson’s 3-D Printing Centre of 
Excellence has also introduced a significant advancement of adopting AM technologies for 
drug delivery systems. Solutions to improve medications adherence for older patients have been 
investigated such as polymer and metal implants, bioprinting, personalised medicines, and AM 
sensor tablets that could send text messages to smart phones. In addition, personalised 
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facemask made of cellulose, locust beans and red seaweed that uses patient information from a 
mobile or a digital camera to construct the mask (Griffiths, 2019). Furthermore, 3D 
musculoskeletal tendon-like tissues were also developed using 3D bio printing by a research 
team from Novartis. Cell-tissue suspension mixed with photo-polymerised gelatin-
methacryloyl was printed in a dumbbell shape onto novel potholder. The cells also exhibited a 
high viability in good tissue differentiation (Laternser et al., 2018). Moreover, researchers from 
Roche and Organovo have printed human liver composed of hepatocyte (patient-derived 
parenchymal) and non-parenchymal cell populations to simulate drug-induced liver damage 
and differentiate between compounds with different toxicity levels (Nguyen et al., 2016). The 
trend towards digitalisation in pharmaceutical industry was triggered by the great potential of 
AM, personalisation, and control over drug release and sustainability within the body and how 
the pharmacodynamics of the medication can be improved by altering its structure, shape, and 
composition. Personalized drug delivery systems have shown to be a reliable approach in 
treating patients considering their personal conditions. Although additive manufacturing 
enabled the potential for new possibilities in drug delivery, the concept behind it and how it 
works is remarkably very simple. 
The case studies discussed in this review revealed many potentials that AM holds for future 
drug delivery systems. However, there are still challenges that need to be addressed in order 
to penetrate AM technology widely within industry and community. Five of seven of AM 
standard technologies have been implemented to develop pharmaceuticals medications, see 
Figure 29a. These techniques are vat polymerization, material extrusion, powder bed Fusion, 
materials jetting, and binder jetting, Figure 29a. The figures show that vat polymerization, 
material extrusion, and powder bed fusion shares similar research amount while direct energy 
deposition and sheet lamination found no applications in drug delivery. In particular, FDM 
and Inkjet printing technologies was found to be interesting to pharmaceutical industry because 
of its ability to print multiple materials with high precision and low cost. In addition, the 
technologies have many similarities with the current production technologies. However, the 
low productivity of 3D printing is one of the barriers that needs to be addressed. Conventional 
technologies can manufacture over than 1.5 million tablets, which cannot be achieved using the 
current 3D printing technologies. In addition, 3D printing offers tablets with rapid drug release 
and a high drug loading, which is difficult using conventional technology. Furthermore, oral, 
implants and scaffolds drug delivery fabricated using AM were the most researched 
applications while rectal, vaginal and transdermal patches show the least interest by 
researchers as shown in Figure 29 and Figure 30. However, this does not mean they were less 
important, but this was mainly because they are often used by specific patients in terms of 
gender, age, and type of disease. The increased amount of research on using AM technologies 
in areas such as oral, scaffolds and implants drug delivery is triggered by the many factors 
such as the ability of AM to control the drug release. AM to realise flexibility in tablets 
formulation with multi-objective release profiles. It helps improvements in innovative drugs 
such as poly therapy and fixed-dose combination (FDC) with various medication release. In 
addition, the AM has ability to produce complex designs of oral tablets with tailored density 
loaded with the prescribed drug. Furthermore, complex geometries scaffolds and implants 
allow body tissue and fluid to flow freely, hence, improve osseointegration of the devices. 
The discussed studies showed that addition of the medication to scaffold and implants by 
either coating, mixing, or as a reservoir helped to overcome inherent problems such as 
infection, stress shielding, and enabled a faster healing process of patience. Additional 








Figure 29: Research amount of (a) AM Techniques used in Drug Delivery Systems, (b) drug 




Figure 30: Current research trend between AM technologies and drug delivery systems.  
 
Although the current research work seems to be bringing us closer to understand the potential 
and limitations of AM technologies for drug delivery applications, there is still a lot of work 
needed to enable the technology widely into the pharmaceutical market. AM can fabricate a 
wide range of materials using commercial printers. Therefore, the materials and equipment used 
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the use of high-temperature steam, which may only a limited number of materials, particularly 
metals, and ceramics while the use of polymers may require other less aggressive sterilisation 
methods. The limited number of in vivo studies and the difficulties to scale up these 
technologies are other challenges that restrict the penetration of this technology further. 
Pharmaceutical companies are required to spend much efforts and money to modify their 
production line with biocompatible grade printers that can fulfil the mass/patch production 
nature of this sector. Environmental impact and sustainability of AM are limitations that require 
a great depth of understanding. Although material saving of AM is great, there is still a gap in 
recycling of AM materials. For example, recycling plastic waste into filaments is a reliable way 
to solve this problem using commercially available extruders. However, issues such as mixing 
of drugs, carrier polymers, colours, and material degradation can lead to a significant issue to 
the properties of filaments.  
5. Conclusions  
The review showed that AM technologies allow customization of drug delivery systems to fit 
patients’ needs and health conditions. The progress in this area is supported by the progress in 
computer-aided design (CAD) and computer-aided manufacturing (CAM) that enable rapid and 
accurate scanning and designing of patient organs. Over the past few years, implementing 
additive manufacturing for drug delivery systems has remarkably helped to discover new routes 
to develop novel medications. The unique characteristics of developed AM drug delivery 
systems including controlled release profile tablets and suppositories, personalised microneedle 
detrimental patch, drug-coated scaffold, and drug-eluting implants are now achievable with the 
use of AM. In orthopaedics, for example, AM technology has managed to change the 
perspective of bone fracture treatments. With the unique capabilities of AM, drug-loaded 
implants and/or scaffolds with complex geometries and high resolution can be used to speed up 
the healing process and restore bone shapes and strengths. In addition, the effectiveness of oral 
drug delivery dosage can be significantly improved by controlling the drug release process and 
the interior structure of the tablets. Such control would allow the drug to provide the body with 
the exactly needed amount of the medication at the time it is needed, minimizing any overdose 
side effects. Technologies such as FDM, SLA, SLS, and SLM have been extensively used to 
fabricate drug delivery systems. FDM has been proven to process wide range of oral dosage 
tablets with complex formulations and geometries. SLA techniques showed high-resolution 
drug devices and microneedles transdermal patches. On the other hand, technologies such as 
direct laser deposition and sheet lamination have not been investigated in this field because of 
their either processing nature or the quality of their products. Clinical evaluations of the 
developed systems by either academia or industry showed a great potential. Pharmaceutical 
companies have started to revolutionize the research and production line aiming to provide 
effective dose to patients. Although AM has successfully developed functional products in other 
industries such as automobile and aerospace, AM of drug delivery is still faces several technical 
and regulatory challenges before a wide adoption in the pharmaceutical industry. In particular, 
research on pharmaceutical materials recycling, quality control, and the effect of inherited 
issues of AM such as surface roughness, internal defects post processing, and resolution are 
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